Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult males/Females aged 18\~80 years~2. Patient who are taking NSAIDs for the treatment of rheumatoid arthritis~3. Patients who belong to ACR functional class 1, 2, 3~Exclusion Criteria:~1. Patients who belong to ACR functional class 4~2. Patients who are hypersensitive to clinical trial medicines or excipient~3. Patients who have experience of Cerebrovascular bleeding, bleeding disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Pelubiprofen 30 mg (Type: EXPERIMENTAL): Pelubiprofen 30 mg, tid
- Celebrex 200 mg (Type: ACTIVE_COMPARATOR): Celebrex 200 mg, tid

Based on this trial design, predict the completion outcome and termination type (if applicable).